Funded by private investors and governments, cancer tests of blood and urine are coming to market.
How much does it cost to bring to market a diagnostic test that’s able to measure cancer without a tissue biopsy?
In the case of Trovagene, almost $100 million.
That’s the cumulative loss, or expense including salaries, R&D, and office space, the money-losing San Diego biotechnology outfit has run up since 1999, when it set out to test for cancer from a cup of urine. Just like recently developed cancer blood tests, the diagnostic the company started offering in May searches for telltale scraps of tumor DNA released by dying cancer cells. The amount of tumor DNA that ends up in urine is a readout, the company says, of whether a tumor has been destroyed or is still growing.
Wall Street analysts expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The idea of such liquid biopsies has leapt to prominence in just the last year. Cancer researchers now expect that the tests will offer a noninvasive way to monitor cancer, find the genetic mutations driving a tumor, or even diagnose it early, before symptoms start. It’s an innovation so big that Wall Street analysts at JP Morgan expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The first DNA blood test for cancer in the United States was commercialized in 2014 by Guardant Health, a venture-backed California company, and tests to spot cancer DNA in blood, urine, or spinal fluid are now in development by a growing number of companies but remain a risky bet for investors.
One pioneering researcher, Dennis Lo, is now tracking more than 20,000 people in Hong Kong to see whether blood screening can catch liver cancer early. Some of his early and ongoing work was paid for by a $1 million grant from the Kadoorie Charitable Foundation, the charity of Hong Kong billionaire Michael Kadoorie, and he later won a $4.25 million award from the Hong Kong government. “It took us about 10 years to convince people to fund us,” he says. Lo says he recently cofounded a company called Cirina to develop blood tests, and he expects initial financing of $12 million from investors.
Investors in the new tests could be disappointed, because while developing a new diagnostic can cost as much as creating a new drug, it’s notoriously hard to make any money off diagnostic tests.
Read more: Bankrolling the 10 Breakthrough Technologies: Liquid Biopsy
The Latest on: Liquid Biopsy
[google_news title=”” keyword=”Liquid Biopsy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Liquid Biopsy
- Nigerian biotech startup becomes first African lab to offer liquid biopsy to advance cancer diagnosison May 9, 2024 at 2:29 am
Nigeria-based biotechnology startup, Syndicate Bio. has partnered with SophiaGenetics, a cloud-native software firm specializing in data-driven medicine, to become the ...
- Liquid biopsy market to reach $11.3b by 2029on May 8, 2024 at 10:58 pm
By clinical applications, therapy selection held the largest market share in 2023. The global liquid biopsy market is expected to reach $11.3b at a compound annual growth rate (CAGR) of 11.9% until ...
- The First Lab in Africa to Make Comprehensive Genomic Profiling and Liquid Biopsy Accessibleon May 8, 2024 at 5:00 pm
The implementation of the new genomic profiling and liquid biopsy technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance ...
- Liquid Biopsy Market Worth $11.3 billion | MarketsandMarkets.on May 8, 2024 at 7:38 am
Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of ...
- Liquid Biopsy Market Worth $11.3 billion | MarketsandMarkets™.on May 8, 2024 at 7:30 am
Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new ...
- U.S. Liquid Biopsy Market to Attain Valuation of USD 12,004.9 Million By 2032: Astute Analyticaon May 8, 2024 at 2:30 am
New Delhi, May 08, 2024 (GLOBE NEWSWIRE) -- The U.S. liquid biopsy market size was valued at US$ 3,786.2 million in 2023 and is projected to surpass a market valuation of US$ 12,004.9 million by 2032 ...
- Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Careon May 7, 2024 at 5:00 pm
However, without awareness of the barriers to adoption of this new technology and a willingness to build mitigation efforts into the implementation of widespread liquid biopsy testing, the ...
- SOPHiA GENETICS Reports First Quarter 2024 Resultson May 6, 2024 at 11:45 pm
while also continuing to build off of the significant momentum of our new Liquid Biopsy offering with the launch of MSK-ACCESS ® powered with SOPHiA DDM™.” Reached 463 core genomics customers as of ...
- Pancreatic Cancer Is Hard to Detect in Early Stages. A New Blood Test Could Helpon May 3, 2024 at 11:46 am
A liquid biopsy can detect 97% of stage 1 and 2 pancreatic cancer cases, according to an early clinical trial. Blood tests could help improve early detection for the deadly cancer.
- Tumor Trash or Treasure? Liquid Biopsy for Colorectal Canceron April 30, 2024 at 5:00 pm
At Weill Cornell, he's the director of colorectal cancer research, as well as the precision medicine director for liquid biopsy research at the Englander Institute of Precision Medicine.
via Bing News